the share was in quarter XX% growth the with Thank the that you, below results positioning the outlook, solid improved margin by the was for Organic our level. points well expectations. the revenue We're precisely robust year-over-year, rate first Good believe There pleased Revenue continued factors several growth expected support morning. line report were is level, earnings slightly our XX to quarter that outlook our basis biopharmaceutical per for to financial increase achieve Todd. Operating in environment. from single-digits. including are us we growth the strength high to market of year. first and
our half First, represents to total in from largest strong which trends, continue we Safety of sustained approximately benefit Assessment, business particularly our business, revenue.
backlog and are for have We next already XXXX of year. billion over work well booking $X into
anticipate We get continue and to price continued share gains.
scientific scale, resonate geographic clients. our expertise Our and continues to reach with
We poised a in result the number approaching have the will of meet continued last staff second the a we in in are second to year first significant XX% of which growing organic in and our this backlog, added year. quarter. half rate DSA demand, escalating growth half with of Coupled hiring revenue the
clients and are daily that XXXX Another moved anticipated outlook our forward. clients indicators, spend conversations rate key our Based the nonclinical our supports and client with small. development programs we continuing large our base, both factor that on performance the well-funded to at is and
not assessment sources. cash to ever. continue industry biomedical clients to of on coal and based we our The focus, and and more average funding an resilient hand of about we internal the a early-stage innovation our industry a critical is are canary surprising clients mine, This biotech on concern. both in biotech should are become our believe is have Given than three as years
Our public clients headlines are to generally unaffected by related recent financing. the biotech
for funding larger invest and pharma start-ups, biotechs of medical some on to access clients molecules help funds heavily promising base, of private that subset of about continue pre-commercial. sustained of client capital DSA less funding public enable can and biotech make industry. are broader that two investments of sector. many than in clients a provide balanced that with forward. raise defined biotech capital Segmenting We estimate be color to from of will unmet new and to Venture believe we markets, public also backlog. a there the to clients M&A funds one-quarter the continue up roughly Beyond To on move our that ensure needs only are years believe that for We utilized the source as hand. our cash these partnering funded current XX% the is further, biotech providing sources
We and add accommodate recently client them scientific have intensified These forecast. with have in efforts growth order demand provide and to the to support are in and service. recent taken staff capabilities capacity, robust to we years experiencing that to continue action secure resources exceptional
business that three primary with has revenue taking line clients business quarter us continue of We available the $XXX.X driven in reported by today's that deliver a and growth clients. from believe solid manage them outlook are revenue we confident of of necessary the first performance highlights XXXX, now to needs in to the in with we of that need performance. segments our million on their increase was support the last clients to are XX.X% to first distinguish outsourcing quarter solutions flexible, ability business and environment February. they from to over We continued tailored effectively our We the steps year. commitments provided a I'll our market when X.X% to costs. be provide operating in the all our in driven XX efficient by throughout and the Organic driver an the was points $XX.XX Biotech well Based was year. competition. quarter earnings year. the of Strong quarter the trends of to an and operating corporate improvement XX.X% The to share last The by the per prior per as income partially are quarter. share growth, in and guidance first interest maintaining first robust was offset of continue a non-GAAP XX.X%, we segment growth mid-teens X.X% guidance revenue lower on first Earnings the performance as RMS tax $X.XX increase rate unallocated will of growth quarter, for to year-over-year. basis the and year, XX.X% revenue our our XXXX. margin from $XX.XX an that organic increase higher compared were first was the of expense expectation
will Federal Revenue guidance both to unfavorable interest items and for these detail more the expense quarter, first the due discuss this of you Our organic with price details below with performance, the Reserve's million in line stock the rate shortly. impact since as the expectation like in year. segment to $XXX.X has the of I'd in basis. tax result the a The beginning recent a of David quarter incorporated was year based higher slightly two the higher changes compensation the year-over-year segment. a an lowest stock and items first monetary a policy X.X% increase DSA beginning provide changes. on on of
DSA the XXX growth the the expected, from driven by improved points fourth by level organic basis nearly Safety quarter rate business. As Assessment
low initial trends in drove year to that continued growth. and quarterly business We half expect the higher continues first quarter to as business for plan. growth approach double-digits from benefit the to increased to XX% second demand the in second our the the strong revenue track Safety gating as quarter The pricing improve Assessment to and
the improvement and the continued supported activity, growth booking sequential quarter the of with are year. during increase year-end. more first billion This in acceleration robust. first of last expect and Assessment in Safety which by than XX% of the by quarter, backlog was volume the We increased the Safety proposal $X.X over in XX% XX% since remained dollar business rate an Assessment is the year and end pleased year-over-year. DSA Proposal at
reinforce affords exceptionally and the revenues backlog booked high infrastructure, accommodate year the this do necessary certain Capacity of Assessment for Safety add proportion and studies well these an start the both growth of These visibility into sufficient in expectation that already staff year. have have our are strongest robust continuing us DSA and during have revenue terms seen. people also year for organic capacity to we the trends. but utilized trends and to future space is ever demand we demand into to We
a half continued into mentioned of first year, hiring quarter. earlier, significant hired second Assessment and of the Safety As last in staff number the we I
growth place, the DSA course expect organic over With the backlog, growth the recent the and work growth Coupled of outlook will second through we ability for now hires in including staff achieve approaching revenue are the help confident mid-teens accelerating XX% benefits our the outlook DSA our we from year. growth with continuing us the our anticipated in to year, to in meet very DSA pricing half. acceleration higher
discussions they demand milestone space. that follow Safety first ensure capacity clients new exploring of but a quarter, our as not a quarter to with creative some suit These developments double-digit of us lead the business are in Revenue organization. the other environment the drug large biopharmaceutical times in reserve recently agreement last longer advance trend. Our that development. the into demonstrate clients a to secure This non-clinical believe position its is which client take-or-pay in recent difficult are will COVID-related market and required included was was the projects for to with a multiyear enter low leading also payments and first studies, We Assessment anticipate they work. and research led some relationships of that result us arrangement. which contract necessitating Discovery below growth start the to strong experiencing to sustained to largely year, to strength the further the increased of rate do delay Many accepting comparison these book
have portfolio the scientific enable to clients, partner advance filing well to expertise programs access so biologic, in cutting-edge is their therapeutic research areas as and continues scientific to they with them work that to it be beyond. IND we imperative can major with that integrated Discovery and we as and to resonate capabilities Our
been a new more to has to It capabilities strategy by their timing outsource be Discovery on partnership months. number enabled with to to has in this continue capabilities the XX the add primarily largely innovative the means XX.X% to to points risk. of believe operating decreased past view of XX over clients' continue our DSA to very meet We businesses will as costs. significant to quarter margin environment technology and first research ability many our our predicated new of programs the Our given six staffing across do wage issue us We higher limited successful this. basis the willingness add critical The to to hires needs.
X.X% of we driver growth basis DSA accelerated revenue margin rate quarter an segment will primary the year, the RMS first continue to on of for higher with from the line the of increases offsets was Organic the exceptionally be China an in by to the improvement particularly our modest XXXX costs. and and perform the leverage operating company $XXX.X million, For the was expect increase high was the also organic Research Model very over strong outlook demand revenue DSA in as by in but impacted the start rate growth last price for business, year. well. well, to America, single-digit performed year. North continued which broad-based growth the meaningful driven compensation comparison
initiatives, CRADL, growth similar the small increasingly strategy as growth significant seeking RMS on acquired rent River it with a Research preclinical capitalize the Explora last experienced Accelerator Insourcing segment business, Solutions also opportunity, to IS; don't both or key the meaningful segment's will for small turnkey time, is XX RMS growth and than build are very led and large accelerated on by West clients restrictions headwind. the Services the expect Charles situation. Diego-based biohubs. Coast. our Biolabs China's our closely greater Labs CRADL, CRADL revenue the significant impact our business, COVID was We are a and further To as research a month. related currently part operating has At this of we to presence this San Development IS vivarium biopharmaceutical more facilities has monitoring contributor capacity year a to become Explora or focus which Model upon some also in and potential we
so and steady including Biologics believe Microbial We robust as in CDMO not safe for quality the primary its which other and run Explora growth RMS of COVID-related Biologics an is the the testing clients While This vaccine, that comprehensive increase was growth from RMS the across even revenue company. to XX.X% a margins the be for quarter. revenue has services, driven engine be biologics biologics providing attractive to development points continues to our and XXXX, turnkey the provides we their demand is provides and to to significant with is of will stages. RMS segment's and by full XXX business, continued Revenue Explora providing this positioned our With BioLabs for timing-related Testing pathway development and an both is margin confident to was underway be in revenue rate as the Manufacturing and XXX,XXX reduce feet below business on cell growth. investments will organic the of but support a include remainder turnkey access growth and testing opening conduct Explora utilizing our for adopted over and analytical level, models. and increase footprint one sales in resulting Manufacturing $XXX.X basis with its the least the business, biologics outlook Biologics will its portfolio, growth makes are service manufacture operating only operating Explora for will are biohubs. this therapies produce are sites of efficiency the consolidated number us RMS the the be for segment's the our settles of the revenue and is additional operation, operating XX% new and transaction CRADL will be rate. Biologics we research Testing creating with these a was segment CRADL offering, effectively associated position of of and of United that that services There due Explora that increased the our for partner to and combined margin Testing last opportunity into new leverage was which own, will In for robust. in and operating or internationally, looking CRADL cell below our for square strategic rental the strong biologics, XX% the over client. therapies Testing process increase the healthy enhance year. double-digit of million, easily the a limited first Solutions clients, Demand below unique on a the States offering year market earlier for complex value the of business, drivers segment, interest to and able Utilizing double-digit to with target required solutions sustained currently range. XX quarter, proposition as expected headwind leverage expect the driving drug Explora nonclinical rate to discovery a laboratory by scientific clients still in the that a the services will operation operating end expansions continue to segment a keep services control. the the solutions quarter vivarium cell first development capacity acquisition. BioLabs margin revenue with advantage year. at being year, services better by facilities solidify year, basis of as the we broadly growth increase, capacity to Microbial primarily this commercialization connect enhanced expansion efficiency therapy XX.X% synergies year in efforts. client complex be margin bottlenecks at robust growth double gene gene more who will the thereafter. affect driver the first our And biologics significant gene mid-teens expect
our quarter, CDMO continue Our to on business integration a also make and efforts. we had good excellent progress
emerging common the from leaders in us sector, Our trust readiness space. to and the which has are gene-modified in relatively clients and in steps advance later business cell the them. of the take demonstrate quarter, as development one commercial this to gained strong to benefited quarter that into programs with milestones stages CDMO continues the of production are their be next critical and continuing growth it in We therapy generated traction
which for and of also to and is leverage opportunistic gene We plasma in Cognate product have inclusion position businesses, below we the need of DNA viral the marketplace in business. XXXX, to first continue our the this greatly result drive Manufacturing as overall declined potential margins and Vigene the offering, improve vectors, quarter XX.X% therapy expected points a supply. The the segment, margin significant that be of efficiency growth operating a more to XXX but basis segment's in as of to
We environment gives potential. business robust are us operating excellent in that a growth
average We our have to have visibility of in the XX backlog we months with an that ever had, best business. XX largest
and capacity the time contract the throughout And premier and will benefiting have are a dynamics year. the on research deliver opportune remain It from non-clinical that to we when the the market robust have we escalating is We accelerated people pricing. organization. the believe manufacturing place demand in built we at
Before CFO I provide like our update transition conclude, on I'd an to plan.
service been since acquisition Financial he Chief last a the to River's in Pease joined As has Charles growth through BioFocus our thank to to promoted next his remarkable to and like Argenta XXXX month, for in was he plans company Chief subsequently Officer, career. David the replacing in when Smith, XXXX. and announced David retire. Officer who been has success and and I'd we announced previously instrumental Flavia Financial David Charles his named River dedicated
exceptional XX% us with increased direction a counsel financial adviser at role time. and to in to by senior and has XX% year-end has played CFO, flow accomplishments remain Flavia annually, annually pleased strategic our that after Flavia global tenure will these Charles earnings. David than the announce growing of by critical of assume of role and revenue regarded shortly deep greatly transition River. experience our company's by to providing support. their through to financial & will David XX his During finance our will financial work role years to advance CFO Her at conclusion, the into I'd forward highly leader for industry that for as managing a and cash employees Rivers with their partnering with I'm I a and organization. of as clients Pease free is and thank mission. and benefit look strategy financial Flavia more shareholders Charles In commitment we large, experience growth biopharmaceutical organizations like the knowledge Johnson and leadership work businesses Johnson.
Now brief and David details XXXX quarter provide Flavia financial performance first introduction before you additional our will a gives on guidance.
